Paradigm Biopharmaceuticals Issues New Shares Amid Drug Development Focus

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. has issued 40 million fully paid ordinary shares without disclosure under the Corporations Act, affirming compliance with all relevant regulations. The Melbourne-based company is focused on advancing its late-stage drug developments, particularly its injectable treatment for diseases like osteoarthritis and mucopolysaccharidosis.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.